APR 02, 2020 5:40 AM PDT

Diagnosing Cancer: SMOC2 and Thyroid Cancer

WRITTEN BY: Jasper Cantrell

Thyroid cancer is the most common of the endocrine cancers, with papillary thyroid carcinomas (PTCs) being the most common form. Thyroid cancer has excellent diagnostic tools, yet there are still some cases that progress post treatment and a few that are not caught at all. A group from Jeju, South Korea decided to investigate SPARC-related modular calcium-binding protein-2, or SMOC2, as a potential tool for further diagnostic tests to catch recurrence early on.

SMOC2, usually a regulator of a cell’s interaction with the surrounding environment during development or disease, has been implicated in several processes related to the progression of cancer. Using this information, the group began to measure the levels of SMOC2 expression in normal thyroid tissue versus PTC thyroid tissues.

The group began by using reverse transcription PCR to measure the mRNA encoding SMOC2 in normal thyroid tissue against several forms of thyroid cancer. They found that SMOC2 expression was lower in almost every cancer sample compared to normal thyroid samples. Next, they took a large sample size of 338 PTC samples and directly stained for SMOC2. The results, showing a significantly lower level of SMOC2 in PTC samples compared to regular thyroid samples, which concurred with the previous mRNA measurements.

Unfortunately, not every result was as clear cut. The thyroid cancer nodular hyperplasia did not follow the same trend rest of the thyroid cancers, retaining normal levels of SMOC2 expression. Follicular adenomas also failed to produce statistically significant data in SMOC2 expression testing. The group tried to investigate why SMOC2 would be down regulated in PTCs, looking at epigenetic methylation of SMOC2's DNA. The sample sized proved to be to small however, and again could not produce much statistically significant data.

The group concludes “Our findings of SMOC2 expression down-regulation in PTC and its association with improved clinical outcomes clearly suggest that SMOC2 likely acts as a tumor suppressor in thyroid cancers.”. Even though some of the results proved inconclusive, the work done here showed productive insights for the possible use of SMOC2 as a secondary biomarker in tests against thyroid cancer.

Sources: Nature, OncLive

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
OCT 21, 2020
Cancer
Can Excess Fructose Cause Liver Cancer?
OCT 21, 2020
Can Excess Fructose Cause Liver Cancer?
Hepatocellular carcinoma, aka liver cancer, is an ever-increasing issue in the western world. While the lion’s sha ...
OCT 26, 2020
Chemistry & Physics
Fighting mesothelioma with gold nanotubes
OCT 26, 2020
Fighting mesothelioma with gold nanotubes
New research published in the journal Small details how gold nanotubes could be used to treat mesothelioma cancer. ...
NOV 30, 2020
Cancer
Using deep learning to identify breast cancer biomarkers in mammograms
NOV 30, 2020
Using deep learning to identify breast cancer biomarkers in mammograms
A team from Massachusetts General Hospital (MGH) has developed a deep learning model capable of predicting a patient&rsq ...
DEC 02, 2020
Cancer
Telomere shortening doesn't only indicate ageing...
DEC 02, 2020
Telomere shortening doesn't only indicate ageing...
While telomere shortening has been thought to be an adverse sign of aging, new research suggests that the shortening of ...
DEC 15, 2020
Cancer
New combination therapy may help patients with treatment resistance
DEC 15, 2020
New combination therapy may help patients with treatment resistance
New research from scientists at the UCLA Jonsson Comprehensive Cancer Center showcases a novel combination therapy that ...
DEC 20, 2020
Cell & Molecular Biology
Chromatin Doesn't Behave Like a Liquid or Solid - It's a Gel
DEC 20, 2020
Chromatin Doesn't Behave Like a Liquid or Solid - It's a Gel
A cell's nucleus has to hold the entire genome. To do that, the DNA has to be carefully arranged and compacted by protei ...
Loading Comments...